BDSXBiodesix, Inc.

NAS · US · Healthcare · Diagnostics & Research · biodesix.com

26.63USD+4.27%Mkt Cap: 280.98M $P/E: —3d ago

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of …

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap280.98M $

Enterprise Value295.34M $

Revenue (TTM)102.94M $

Gross Profit71.78M $

Net Income (TTM)-35.27M $

Revenue/Share11.59 USD

Last Price26.63 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees334

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-109.23

PEG—

EV/EBITDA-19.68

EV/Revenue2.87

P/S2.46

P/B27.72

EPS (TTM)-2.94

EPS (Forward)-0.22

52W Range

5.26098% of range27.11

52W High27.11 USD

52W Low5.260 USD

Profitability

Gross Margin81.11%

Oper. Margin-20.01%

EBITDA Margin-14.58%

Profit Margin-39.85%

ROE1430.63%

ROA-40.31%

Growth

Revenue Growth34.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-23.27M $

CapEx (TTM)403.00K $

FCF Margin-10.58%

FCF Yield-3.88%

Net Debt41.80M $

Net Debt/EBITDA-2.79

Balance Sheet

Debt/Equity-29.56

Current Ratio2.85

Quick Ratio2.56

Book Value/Sh0.8670 USD

Cash/Share2.843 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:20

Split DateSep 15, 2025

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)34.00 USD

Upside (mean)+27.7%

Target Range27.00 USD – 40.00 USD

$27.00+27.7% to mean$40.00

# Analysts6

Ownership

Shares Out.10.55M

Float4.98M

Insiders40.13%

Institutions41.41%

Short Interest

Short Ratio2.3d

Short % Float2.58%

Short % Out.1.49%

Shares Short157.19K

Short (prev mo.)105.43K

Technical

SMA 5021.02 (+26.7%)

SMA 20013.91 (+91.4%)

Beta0.56

S&P 52W Chg18.16%

Avg Vol (30d)84.86K

Avg Vol (10d)115.27K

Technical Indicators

RSI (14)68.7

MACD1.2651

MACD Signal1.0612

MACD Hist.+0.2039

BB Upper26.22 USD

BB Middle23.01 USD

BB Lower19.80 USD

BB Width27.89%

ATR (14)2.094 USD

Vol Ratio (20d)3.20x